Torna all'elenco degli studi
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
CODICE STUDIO
NCT06045806
TIPOLOGIA
Prima linea giovani, Prima linea anziani
NOME SPONSOR
Bristol-Myers Squibb
DESCRIZIONE
Trattamento
ARM1:
Biological: idecabtagene vicleucel
Specified dose on specified days
Other Names:
- BMS-986395
- Abecma
- bb2121
- ide-cel
Drug: Lenalidomide
Specified dose on specified days
Other Names:
- Revlimid
- LEN
Drug: Fludarabine
Specified dose on specified days
Other Names:
- FLUDARA
- BENDARBIN
Drug: Cyclophosphamide
Specified dose on specified days
Other Names:
- ENDOXAN
- CYTOXAN
ARM B
Drug: Lenalidomide
Specified dose on specified days
Other Names:
- Revlimid
- LEN
FARMACI UTILIZZATI
Lenalidomide, Talquetamab (CAR-T)